NH
Publicaties op Oncologisch.com
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as Eerstelijns Behandeling for Unresec...
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemoth...